Micot Pharma presents MT200605 Huntington’s data at MDS 2026

what happened

Asian Corporate Newswire reports that Micot Pharma (2335.HK) presented an electronic poster at MDS 2026 in Seoul with the first nonclinical findings for MT200605 in Huntington’s disease and Phase I data from healthy volunteers. The congress took place from October 4 to 8, 2026. The company had previously announced positive Phase II results in acute ischemic stroke (AIS).

In a transgenic Huntington’s disease mouse model, MT200605 improved motor coordination and reduced whole-brain, cortical, and striatal atrophy. The study also found preserved levels of the striatal neuronal marker DARPP-32 and lower aggregation of mutant huntingtin protein in the cortex. In vitro tests showed activation of TrkB and downstream AKT signaling, together with increased mitochondrial ATP production.

The Phase I study was randomized, double-blind, and placebo-controlled, with single-ascending-dose and multiple-ascending-dose stages. No serious adverse events, deaths, or withdrawals caused by adverse events were reported; drug-related events were mild and self-limiting. Exposure rose with dose, while no appreciable accumulation was observed after repeated dosing.

MT200605 targets the BDNF/TrkB pathway, which is involved in neuronal survival, synaptic maintenance, and mitochondrial stability. According to the company, the candidate is also designed to reduce oxidative stress and microcirculatory impairment. The AIS Phase II trial enrolled 360 participants; the medium- and high-dose groups recorded higher shares of patients reaching an mRS score of 0–1 at 90 days than the placebo group. In the high-dose group, the odds of functional recovery were more than 100% higher than with placebo, while the incidence of acute kidney injury was more than 80% lower. The report ends while describing existing neuroprotective approaches for AIS.

why it matters

The findings broaden the stated development rationale for MT200605 from acute stroke to chronic neurodegenerative disease, although the Huntington’s evidence remains at the preclinical and healthy-volunteer Phase I stages.

instruments